Recombinant Tissue Plasminogen Activator (rtPA) in the Treatment of Macular Hemorrhages
DOI:
https://doi.org/10.48560/rspo.23931Keywords:
Intravitreal Injections, Retinal Hemorrhage/treatment, Recombinant Proteins, Tissue Plasminogen ActivatorAbstract
Macular hemorrhage is a frequent complication of retinal macroaneurysms and represents a threat to central vision. We report the surgical use of recombinant tissue plasminogen activator (rtPA) in the treatment of macular hemorrhage.
Two eyes of 2 female patients with macular hemorrhage from ruptured retinal macroaneurysms were treated with subretinal rtPA injection. Visual acuities on admission were of counting fingers (<20/400) in the 2 eyes treated. Best corrected visual acuity improved to 20/100. No major intraoperative complications were reported.
Macular hemorrhage presents a low rate of spontaneous resolution and, left untreated, portends a poor prognosis. Subretinal injection of rtPA is a challenging, yet effective surgical technique, with rates of hemorrhage displacement reported between 50%-90%.
Downloads
References
Araujo J, Sousa C, Faria PA, Carneiro A, Rocha-Sousa A, Falcao-Reis F. Intravitreal injection of recombinant tissue plasminogen activator in submacular hemorrhage: case series. Eur J Ophthalmol. 2016;26:e49-51. doi: 10.5301/ejo.5000682.
Inoue M, Shiraga F, Shirakata Y, Morizane Y, Kimura S, Hirakata A. Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2015;253:1663-9. doi: 10.1007/s00417-014-2861-6.
Gonzalez-Lopez JJ, McGowan G, Chapman E, Yorston D. Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases. Eye. 2016;30:929-35. doi: 10.1038/eye.2016.65.
van Zeeburg EJ, van Meurs JC. Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration. Ophthalmologica. 2013;229:1-14. doi: 10.1159/000343066.
van Zeeburg EJ, Cereda MG, van Meurs JC. Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm. Graefes Arch Clin Exp Ophthalmol. 2013;251:733-40. doi: 10.1007/s00417-012-2116-3.
Sonmez K, Ozturk F, Ozcan PY. Treatment of multilevel macular hemorrhage secondary to retinal arterial macroaneurysm with submacular tissue plasminogen activator. Eur J Ophthalmol. 2012;22:1026-31. doi: 10.5301/ejo.5000140.
Boiche M, Angioi-Duprez K, Conart JB, Berrod JP. Traitement des hématomes de la dégénérescence maculaire liée à l’âge par vitrectomie et injection sous-rétinienne de rt-PA : résultats préliminaires. J Fr Ophtalmol. 2019;42:e391-e7. doi: 10.1016/j.jfo.2019.02.016.
Chang W, Garg SJ, Maturi R, Hsu J, Sivalingam A, Gupta SA, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol. 2014;157:1250-7. doi: 10.1016/j.ajo.2014.02.007.
Waizel M, Todorova MG, Rickmann A, Blanke BR, Szurman P. Efficacy of Vitrectomy Combined with Subretinal rtPA Injection with Gas or Air Tamponade. Klin Monbl Augenheilkd. 2017;234:487-92. doi: 10.1055/s-0042-121575.
Hillenkamp J, Surguch V, Framme C, Gabel VP, Sachs HG. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2010;248:5-11. doi: 10.1007/s00417-009-1158-7.
Downloads
Published
How to Cite
Issue
Section
License
Do not forget to download the Authorship responsibility statement/Authorization for Publication and Conflict of Interest.
The article can only be submitted with these two documents.
To obtain the Authorship responsibility statement/Authorization for Publication file, click here.
To obtain the Conflict of Interest file (ICMJE template), click here
